EGFR and non-small cell lung carcinoma: In a phase Ib/II study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated NSCLC, 27 of 161 patients (17%) reported AEs that led to study drug discontinuation [28].